• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Genzyme Ventures

edit

Sanofi-Genzyme BioVentures (SGBV) is an important component of Sanofi’s broader global strategy to invigorate external innovation and research that will ultimately lead to new products. SGBV has leveraged the venture capital investment expertise and platform of its predecessor fund, Genzyme Ventures, with a recently-expanded mandate to invest across the more expansive footprint of Sanofi.

Originally established in 2001 as Genzyme Ventures, SGBV invests directly in private early-stage companies with promising new products based on breakthrough science. Today, SGBV is a $100 million fund with a portfolio of direct equity investments in a variety of promising private life-science companies.

Recent Milestones

edit

• 
  Genzyme Ventures — plans to build a manufacturing plant in Geel, Belgium (1/20/11)
  Posted 1/20/11 at 8:36am via masshightech.com
• 
  Genzyme Ventures invested in bluebird bio. (3/12/10)
  Posted 3/12/10 at 6:38pm via fiercebiotech.com
• 
  Genzyme Ventures invested in GlycoMimetics. (12/7/09)
  Posted 10/21/09 at 11:56pm via onbiovc.com
• 
  Genzyme Ventures invested in Fate Therapeutics. (11/16/09)
  Posted 11/16/09 at 11:35am via fatetherapeutics.com
• 
  Genzyme Ventures invested in KaloBios Pharmaceuticals. (12/22/08)
  Posted 6/14/09 at 11:02pm via kalobios.com
• 
  Genzyme Ventures invested in Proteostasis Therapeutics. (8/25/08)
  Posted 6/21/09 at 11:40pm via reuters.com
• 
  Genzyme Ventures invested in TcLand Expression . (12/19/07)
  Posted 3/14/10 at 7:50pm via accessmylibrary.com
• 
  Genzyme Ventures invested in Sirtris Pharmaceuticals. (4/19/06)
  Posted 5/21/08 at 2:11pm via fiercebiotech.com

Investments

Videos

Sources

Genzyme expands Belgium manufacturing plant (masshightech.com) [edit]
1. Genetix raises $35M to advance gene therapies (fiercebiotech.com) [edit]
2. GlycoMimetics, Inc.: Series C $38M (onbiovc.com) [edit]
3. Fate Therapetucis (fatetherapeutics.com) [edit]
4. KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million (kalobios.com) [edit]
5. Proteostasis Therapeutics Secures a $45 Million Series A Financing to Develop Proteostasis Regulator(TM) Drugs (reuters.com) [edit]
6. TcLand expression's Series A adds 8m [euro] for biomarker work. (accessmylibrary.com) [edit]
7. Sirtris pockets $37M in venture funds (fiercebiotech.com) [edit]